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CD59 protects rat kidney from complement mediated injury regulatory proteins on the plasma membrane of host
in collaboration with Crry. cells. In humans, decay accelerating factor (DAF; CD55)
Background. As previously reported, the membrane-bound [1], membrane cofactor protein (MCP, CD46) [2], andcomplement regulator at the C3 level (Crry/p65) is important
CD59 [3–7] are widely distributed in many organs andin maintaining normal integrity of the kidney in rats. However,
vessels and play central roles to protect host cells fromthe role of a complement regulator at the C8/9 level (CD59)
is not clear, especially when activation of complement occurs autologous complement attack. MCP and DAF regulate
at the C3 level. The aim of this work was to elucidate the in complement activation at the C3 level, and CD59 acts
vivo role of CD59 under C3 activating conditions. at the level of formation of membrane attack complexMethods. Two monoclonal antibodies, 5I2 and 6D1, were
(MAC). The protective role of C3 level membrane inhib-used to suppress the function of Crry and CD59, respectively.
itors has been demonstrated in vivo in our previous stud-In order to activate alternative the pathway of complement,
the left kidney was perfused with 5I2 and/or 6D1 and was ies [8, 9] using monoclonal antibody (mAb) 5I2, which
recirculated. blocks the function of rat Crry, a complement regulator
Results. In the kidneys perfused with 5I2 alone, deposition acting at the C3 level [10]. Rat Crry, the target antigenof C3 and membrane attack complex (MAC) was observed in
of mAb 5I2, is the rat homologue of mouse Crry [11],the peritubular capillaries, vasa recta, and tubular basement
which inhibits mouse C3 convertase [12–14]. Broad tissuemembranes. Cast formation, tubular dilation and degeneration,
and cellular infiltration were observed at days 1 and 4, and distribution of rat Crry has been demonstrated [15]. The
they recovered by day 7. Further suppression of CD59 by 6D1 protective role of CD59 has been elucidated in many
significantly enhanced the deposition of MAC and worsened disease conditions, such as paroxysmal nocturnal hema-the already exacerbated tubulointerstitial injury. These effects
turia [4, 6], acute myocardial infarction [16], and xeno-of 6D1 were dose dependent. Perfusion with 6D1 alone did
transplantation [17]. Inhibition of CD59 in the synovialnot induce histologic damage or MAC deposition in the tubu-
lointerstitium. tissues induced transient inflammation [18]. Intravenous
Conclusions. In rats, CD59 maintains normal integrity of the administration of mAb 5I2 induced a transient decrease
kidney in collaboration with Crry in rats against complement- in blood pressure, while mAb 6D1 (a neutralizing mAbmediated damage in vivo.
against rat CD59) [19] showed no effect [8]. In the normal
human kidneys, complement-regulatory proteins at both
C3 and MAC levels are abundantly expressed in most
The complement system functions as a protective ma-
compartments, including peritubular capillaries [20]. Inchinery against foreign microorganisms. One of the key
rats, Crry and CD59 are also expressed in the peritubularmechanisms by which the complement system distin-
capillaries [21]. Blocking of Crry by perfusion of theguishes self from non-self is via expression of complement-
kidney with mAb 5I2 caused increased permeability of
peritubular capillaries [22] and the subsequent intersti-
tial inflammation with deposition of C3 and MAC in theKey words: C3, membrane attack complex, peritubular capillaries, tu-
bulointerstitial injury, renal protective agents. renal interstitium [21]. These data confirm the impor-
tance of rat Crry in the protection against autologousReceived for publication November 18, 1999
complement attack. In contrast, the contribution ofand in revised form March 31, 2000
Accepted for publication May 1, 2000 CD59 has not been fully investigated in the kidney. Sup-
pression of the function of CD59 alone does not induceÓ 2000 by the International Society of Nephrology
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Table 1. Experimental protocolany inflammatory changes in the kidney when comple-
ment activation is not initiated [21]. It remains to be Group Antibodya mg/body 15 minb Day 1b Day 4b Day 7b
elucidated whether CD59 plays protective roles under I 5I2 (0.3) 3 6 6 6
II 5I2 (0.3)16D1 (3.0) 3 6 6 6C3-activated condition. The present work was designed
III 5I2 (0.3)16D1 (0.3) 3 6 6 6to study the role of CD59 in the rat kidney when comple-
IV 6D1 (3.0) 3 6 6 6
ment was activated at the C3 level. The results obtained V Vehiclec 3 6 6 6
in the present work show clearly that CD59 protects a The left kidney was perfused with each dose of antibody
b The number in each column indicates the number of rats examinedkidneys from complement-mediated injury in collabora-
c Modified Tyrode’s buffertion with Crry in rat kidneys.
METHODS
lished by releasing the clamps. The average time requiredAnimals
for the whole procedure was less than 15 minutes.
Male Wistar rats weighing 260 to 280 g were purchased
from Chubu Kagaku Shizai Co. Ltd. (Nagoya, Japan) Experimental protocol
and were allowed free access to food and water. The Rats were divided into five groups. Rats of group I
experiments were performed according to the Animal were perfused with 0.3 mg of F(ab9)2 fragment of 5I2 in
Experimentation Guide of Nagoya University School of 10 mL of Tyrode’s buffer. Rats of group II were perfused
Medicine (Nagoya, Japan). with 0.3 mg of 5I2 F(ab9)2 and 3.0 mg of F(ab9)2 fragment
of 6D1. Rats of group III were perfused with 0.3 mg ofAntibodies
5I2 F(ab9)2 and 0.3 mg of 6D1 F(ab9)2. Group IV rats
Characteristics of rat Crry and mouse mAb 5I2 were were perfused with 3.0 mg of F(ab9)2 fragment of 6D1.
described previously [10]. A mouse mAb 6D1 that inhib- Rats in group V were perfused with Tyrode’s buffer
its function of rat CD59 [19] was also described pre- (vehicle) only and were used as controls. Rats were killed
viously. F(ab9)2 fragments of mAb 5I2 and 6D1 were
at one, four, and seven days after perfusion. To study
prepared as reported earlier and were used in all in vivo
the binding of mAbs and rat complement, rats were also
studies [8, 21]. Mouse mAb 2A1 [23] directed against
killed 15 minutes after perfusion. The protocol and therat MAC was kindly provided by Dr. W.G. Couser (Uni-
number of rats examined are summarized in Table 1.versity of Washington, Seattle, WA, USA). The 2A1 was
labeled with biotin according to the method described by Histology and immunohistology
Guesdon, Ternynck, and Abrameas [24]. FITC-labeled
For light microscopic examination, methacarn-fixedmouse mAb against rat leukocyte common antigen
and paraffin-embedded kidney tissues were cut at 2 mm(LCA; clone OX-1) was purchased from Dainippon
and stained with periodic acid-Schiff (PAS). To assessPharmaceutical Co. (Osaka, Japan).
tubulointerstitial injuries, kidney sections were arbi-
trarily divided into three regions, that is, cortex, outerUrinary protein excretion
medulla, and inner medulla. Using semiquantitative indi-Rats were housed in metabolic cages overnight (16 h)
ces, sections were analyzed for the evaluation of acuteevery other day from day 1 to day 7. Urinary protein
tubulointerstitial damage. In each region, extents of tu-was measured by the pyrogallol red method [25].
bular cast formation and tubular dilation were scored
Kidney perfusion by two blinded observers according to the following cri-
teria: 0 5 normal; 1 5 ,30%; 2 5 30 to 70%; 3 5 .70%To localize 5I2 and/or 6D1 solely in the left kidney
of the pertinent area [21].and to avoid their systemic effects, isolated left kidney
For immunofluorescence microscopy, kidney tissuesperfusion was performed according to the method de-
were snap frozen, cut at 2 mm, and fixed in acetone.scribed previously [26, 27]. Under nembutal anesthesia,
Sections were stained by FITC-labeled rabbit antibodiesthe left kidney of rat was exposed. Polyethylene tubes
against mouse IgG and rat IgG, and FITC-labeled goatwere placed in the left renal artery and vein, and the prox-
antibodies against human C4 (Biogenesis Ltd., Poole,imal portions of the vessels were temporarily ligated.
UK) and rat C3 (Cappel Laboratories, West Chester, PA,The left kidney was perfused at a rate of 2 mL/min
USA). The antibody against human C4 cross-reacts withusing a peristaltic pump. Modified Tyrode’s buffer [26]
rat C4. For the detection of MAC, sections were firstsaturated with 95% O2 and 5% CO2 was used as a vehicle.
treated with avidin D and biotin-blocking solution (VectorAll of the perfusate was discarded through the cannula
Laboratories, Burlingame, CA, USA). They were then in-placed in the renal vein. After kidney perfusion, tubes
cubated with biotinylated 2A1 followed by the incubationwere removed, and the holes in the vessels were repaired
by microsurgery. Then blood circulation was re-estab- with FITC-labeled streptoavidin (Cappel Laboratories).
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Deposition of rat C3 and MAC in the kidney was semi- after perfusion), mouse IgG was still present in the tu-
bules and vascular bundles, but had become almost unde-quantitatively scored according to the extent of deposition
in each region using the following criteria: 0 5 normal; tectable in glomeruli and peritubular capillaries. After
four days, mouse IgG disappeared from the kidney ex-1 5 ,30%; 2 5 30 to 70%; and 3 5 .70% of the pertinent
area [21]. Since normal rat tubular basement membrane cept for weak staining in the vasa recta. In rats of group
IV, 6D1 bound to glomerulus, peritubular capillaries,of cortex was positively stained for rat C3 and MAC
in a focal and interrupted pattern, only circumferential vasa recta, and distal tubules 15 minutes after perfusion.
The fate of 6D1 in the kidney was almost identical tostaining was counted as positive. In renal medulla, C3
and MAC were negative in normal rats. For the analysis that of 5I2 in rats of group I. Staining for rat IgG was
not detectable in any rat throughout the experiment.of interstitial leukocyte infiltration, sections were stained
by FITC-OX1. The number of positive cells was counted Deposition of C3. Fifteen minutes after perfusion/
recirculation, strong deposition of C3 was detected inin randomly selected 10 microscopic fields under higher
magnification (3400). After washing with phosphate- group I, II, and III rats in peritubular capillaries of cortex,
vasa recta, basement membranes of proximal tubules,buffered saline, all the sections were covered with 90%
glycerol containing p-phenylenediamine [28] and were and inner medulla. C3 deposition was also present in
glomerulus at this time, but was not detectable at day 1examined by two blinded observers using an epifluores-
cence microscope (Olympus Optical Co., Tokyo, Japan). and later, whereas at other sites, C3 was present at all
time points. The extent of deposition of C3 was almost
Statistical analysis the same among groups I, II, and III. In rats of groups
IV and V, there was no abnormal deposition of C3.All values are provided as mean 6 SD. Statistical
analysis was performed by one-factor analysis of vari- These data were analyzed semiquantitatively and are
presented in Figure 4. C4 was not detected throughoutance (ANOVA). When significant difference was pres-
ent, statistical analysis was further performed using the experiments.
Deposition of MAC. After perfusion/recirculation,Scheffe’s F-test between two groups. Significant differ-
ence was set when the P value was less than 0.05 (5%). MAC was detected in rats of groups I, II, and III in
almost the same distribution as C3, although glomerular
deposition was absent. MAC deposition was still strong
RESULTS
in these groups, particularly along the cortical tubular
Light microscopic findings basement membrane where circumferential binding of
MAC was observed. The deposition of MAC in peritubu-A significant tubulointerstitial change was observed
by light microscopy in rats of groups I, II, and III. Cast lar capillaries and vasa recta had disappeared by day 7,
whereas the deposition in tubular basement membraneformation, dilation of tubules, vacuolar degeneration,
numerous mitotic figures, loss of brush border, and de- (TBM) still remained at day 7. The degree of MAC
deposition in group II was significantly higher than thattachment of tubular epithelial cells were also prominent
in these rats (Fig. 1). Cellular infiltration was also signifi- in groups I and III. In rats of groups IV and V, there
was no abnormal deposition of MAC in the kidney. MACcantly present (quantitative data are shown in the next
section). The tubulointerstitial changes observed by light deposition was not detected in the glomerulus in any of
the groups at any time point (Figs. 4 and 5).microscopy tended to heal by day 7 in rats of groups I
and III, whereas those changes in group II rats remained Cellular infiltration. In rats of groups I, II, and III,
cellular infiltration was not so prominent at day 1 inuntil day 7 (Fig. 2). In rats of groups IV and V, there was
no histologic alteration in the left kidneys throughout the cortex and medulla. There was, however, significant leu-
kocyte infiltration at days 4 and 7. In addition, the extentexperiments. Further semiquantitative analysis revealed
that the extent of tubular cast formation, and dilation of leukocyte infiltration in group II was significantly
greater than groups I and III. Cellular infiltration wasof tubules was significantly larger in group II rats than
in group I and III rats (Fig. 3). In contrast to tubulointer- most prominent in the outer medulla. In other groups of
rats, cellular infiltration was minimal and did not changestitial tissue, there was no significant alteration in the
glomerulus throughout the experiments in any group. throughout the experiments. Leukocyte infiltration was
not seen in the glomeruli of any of the rats at any time
Immunohistological findings point. These results are shown in Figure 6.
Distribution of antibody in vivo. Fifteen minutes after
Urinary protein excretionkidney perfusion, binding of mouse IgG was seen along
glomerular, peritubular, and medullary capillaries, in- Urinary protein loss significantly increased in rats of
groups I, II, and III compared with groups IV and V atcluding the vasa recta of outer medulla in rats of groups
I, II, and III. Mouse IgG also bound to the basolateral days 0 to 1. The maximum amount of urinary protein
loss in group II rats was significantly larger than in groupsmembrane of the proximal tubules. At day 1 (24 hours
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Fig. 1. Light microscopy at day 4 in groups I and II (A and B ) cortex, (C and D ) outer medulla, and (E and F ) inner medulla. Tubular dilation
and cast formation are seen in rat of both groups, but these changes are more prominent in group II. In the outer medulla, the structure of vasa
recta is not clear in group II (Group I, PAS, 3200, A, C, and E); Group II, B, D, and F).
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Fig. 2. Light microscopy at day 7 in groups I and II (A and B ) cortex, (C and D ) outer medulla, and (E and F ) inner medulla. Tubular dilation
and cast formation are still present in group II, while these changes are almost healed in group I (Group I, PAS, 3200, A, C, and E; Group II,
B, D and F).
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Fig. 3. Semiquantitative analysis of tubular
changes by light microscopy. Note that the
changes are most prominent in group II and
that the tubular changes are still prominent
at day 7. Symbols are: (j) group I; ( ) group
II, (h) group III; ( ) group IV; ( ) group
V; *P , 0.01 group II vs. other groups; **P ,
0.01 groups I or III vs. groups IV or V; #P ,
0.01 groups I or II or III vs. group IV or V;
no significant difference among groups I, II,
and III.
I and III. Urinary protein excretion in group II recovered present work, this notion was confirmed by examining
the effects of kidney perfusion with a large amountslowly, reaching the normal range at day 5, whereas
(3.0 mg in the present study vs. 0.3 mg in the previousgroups I and III had recovered to the normal range by
work) of anti-rat CD59 antibody (6D1; group IV). Thereday 3 and onward (Fig. 7).
was no significant tubulointerstitial injury in this group.
However, once complement activation was initiated at
DISCUSSION the C3 level by blocking the function of rat Crry, CD59
In a previous study, we showed that suppression of was revealed to be playing an essential role to protect
the function of renal CD59 alone did not induce comple- kidneys against autologous complement attack. This no-
ment-mediated tubulointerstitial injury. Our previous tion is supported by the following facts. First, additional
data have demonstrated that regulation at the C3 level suppression of CD59 by relatively large amounts (3.0
was most important for the protection of renal tubuloin- mg) of 6D1 [F(ab9)2 fragment] significantly worsened
tubulointerstitial injury. Since a relatively low dose ofterstitium from autologous complement attack. In the
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Fig. 4. Semiquantitative analysis of deposi-
tion of C3 and MAC in the kidney by immuno-
fluorescence miscroscopy. Note that deposi-
tion of C3 is comparable among groups I, II,
and III, while MAC deposition is most promi-
nent in group II. Symbols are: (j) group I;
( ) group II, (h) group III; ( ) group IV;
( ) group V; #P , 0.01, there is no significant
difference among groups I, II, and III. *P ,
0.01 group II vs. other groups; **P , 0.01
group I or III vs. group IV or V.
6D1 (0.3 mg) was not enough to enhance the 5I2-induced lation was seen in these areas [21]. Hatanaka et al have
shown that the vascular permeability for plasma proteinsrenal injury, it is likely that there is a dose dependency
of 6D1 in the suppression of CD59. Second, the degree was increased after suppression of Crry [22]. Thus, the pri-
mary event in the present model is likely to be the com-of C3 deposition was not different among animals in
groups I, II, and III, while the extent of MAC deposition plement-mediated microvascular injury in the intersti-
tium. Subsequent leakage of plasma proteins, includingwas much more prominent in group II. Since histological
and immunohistological parameters closely correlated complement components into the interstitial compart-
ment, will permit complement activation and depositionwith the extent of MAC deposition, we concluded that
the worsening of tubulointerstitial injury was due to the of MAC in tubular basement membranes and basolateral
membranes of tubular cells. Interstitial inflammation andincreased MAC deposition.
Complement-mediated injury in the renal vasculature, MAC deposition in the tubules will then induce tubular
injury. In contrast to the tubulointerstitium, there wasespecially in the peritubular capillaries and vasa recta,
is likely to be the initial events in the present model of no significant morphological alteration in the glomeruli.
This finding was also reported by Nangaku et al [29].tubulointerstitial injury. The primary binding site of mono-
clonal antibodies 15 minutes after perfusion and recircu- The different responses following functional suppression
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Fig. 5. Immunofluorescence showing deposition of MAC at day 4 in (A and B ) cortex, (C and D ) outer medulla, and (E and F ) inner medulla.
Circumferential binding of MAC was observed along cortical tubular basement membranes (arrow heads) in both groups, whereas deposition is
also detected in peritubular capillaries (arrows), vasa recta (VR), and the medullary capillaries in group II. Staining in these area of group I rats
is faint. C, collecting duct (Group I, 3200, A, C, and E; Group II, B, D, and F).
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Fig. 6. Quantitative analysis of leukocyte in-
filtration in the tubulointerstitium. Note that
infiltration of LCA-positive leukocytes is most
prominent in group II at day 4 and day 7.
Symbols are: (j) group I; ( ) group II, (h)
group III; ( ) group IV; ( ) group V; *P ,
0.01 group II vs. other groups; **P , 0.01
groups I or III vs. groups IV or V.
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Complement-mediated renal injury takes place when
complement activation overwhelms its regulation mech-
anisms. The kidney is an organ that is always exposed
to complement-activating stimuli. The present data dem-
onstrated that Crry and CD59 work together as the im-
portant regulators of complement in the living kidney.
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